Closed-circuit device and methods for isolation, modification, and readministration of specific constituents from a biological fluid source

A method for preparing a purified targeted component from a reactor comprising:

• (a) conducting a reactor fluid from said reactor into a closed diversion circuit comprising (i) an inlet;
• said inlet being connected to (ii) a partitioning chamber comprising fractionation means which allows passage of a fluid fraction containing a targeted component of said reactor fluid while retaining other components of said reactor fluid, said partitioning chamber being connected to (iii) an outlet for returning said reactor fluid to said reactor;
• and (iv) a sequestering chamber comprising a capture support capable of binding to or reacting with said targeted component upon contact with the fluid fraction;
• wherein said sequestering chamber is connected to said partitioning chamber so as to receive the fluid fraction from the partitioning chamber or to return fluid fraction to the partitioning chamber;
• (b) conducting said fluid fraction into said sequestering chamber, whereby at least a portion of said targeted component in said fluid fraction is bound to or undergoes a modification reaction with said capture support;
• (c) optionally carrying out a further modification in said sequestering chamber to modify at least a portion of said targeted component;
• (d) conducting modified targeted component, modified in accordance with step (b) and, if performed, step (c), from said sequestering chamber to said partitioning chamber or to said outlet;
• and
• (e) reintroducing reactor fluid retentate emitting from said partitioning chamber and modified targeted component into said reactor.

A method for detecting or treating a disease or disorder causing the endogenous production of antibodies specific for diseased cells in a subject comprising:

• (a) conducting blood from a mammalian subject suffering from a disease or disorder into an extracorporeal closed circuit comprising (i) an inlet;
• said inlet being connected to (ii) a partitioning chamber comprising filtering means which allows passage of said antibodies of said blood to produce a filtrate while retaining other components of said blood, said partitioning chamber being connected to (iii) an outlet for returning said blood to said mammalian subject;
• (iv) a sequestering chamber comprising a capture support capable of binding to or reacting with said antibodies upon contact with said filtrate;
• wherein said sequestering chamber is connected to said partitioning chamber so as to receive said filtrate from the partitioning chamber or to return the filtrate to the partitioning chamber;
• (b) conducting said filtrate into said sequestering chamber, whereby at least a portion of the antibodies in said filtrate are bound to or undergo a modification reaction with said capture support;
• (c) carrying out a further chemical reaction in said sequestering chamber to modify at least a portion of said antibodies, wherein antibodies modified in accordance with step (b) and/or step (c) are rendered detectable or lethal to said diseased cells as a result of said modification reaction and/or said chemical reaction;
• (d) conducting modified antibodies, modified in accordance with step (b) and/or step (c), from said sequestering chamber to said partitioning chamber or to said outlet;
• and
• (e) reintroducing the blood retentate emitting from said partitioning chamber and said modified antibodies into said subject.